Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sm pharmaceuticals sdn. bhd. - caesalpinia sappan; live attenuated measles virus -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sm pharmaceuticals sdn. bhd. - live attenuated measles virus -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sm pharmaceuticals sdn. bhd. - live attenuated measles virus -

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - measles virus - schwarz strain live attenuated; mumps vaccine rit 4385 live attenuated; rubella virus (ra 27/3 strain) - powder and solvent for solution for injection in pre-filled syringe - 0 percent - measles vaccines; measles, combinations with mumps and rubella, live attenuated

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

serum institute of india pvt. ltd. (siipl), india - measles , mumps , rubella - lyophilized injection - 0.5

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - measles virus - injection, powder, lyophilized, for solution - 3.00 log tcid 50

United States - English - NLM (National Library of Medicine)

a-s medication solutions - measles virus strain enders' attenuated edmonston live antigen (unii: mfz8i7277d) (measles virus strain enders' attenuated edmonston live antigen - unii:mfz8i7277d), mumps virus strain b level jeryl lynn live antigen (unii: 47qb6mx9ku) (mumps virus strain b level jeryl lynn live antigen - unii:47qb6mx9ku), rubella virus strain wistar ra 27/3 live antigen (unii: 52202h034z) (rubella virus strain wistar ra 27/3 live antigen - unii:52202h034z) - m-m-r® ii is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older. do not administer m-m-r ii vaccine to individuals with a history of hypersensitivity to any component of the vaccine (including gelatin) {3} or who have experienced a hypersensitivity reaction following administration of a previous dose of m-m-r ii vaccine or any other measles, mumps and rubella-containing vaccine. do not administer m-m-r ii vaccine to individuals with a history of anaphylaxis to neomycin [see description (11)]. do not administer m-m-r ii vaccine to individuals who are immunodeficient or immunosuppressed due to disease or medical therapy. measles inclusion body encephalitis {4} (mibe), pneumonitis {5} and death as a direct consequence of disseminated measles vaccine virus infection have been reported in immunocompromised individuals inadvertently vaccinated with measles-containing vaccine. in this population, disseminated mumps and rubella vacc

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme australia pty ltd - rubella virus; mumps virus; measles virus -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sharp & dohme (malaysia) sdn bhd - live attenuated measles virus; live attenuated rubella virus; live attenuated mumps virus -

Malta - English - Medicines Authority

glaxosmithkline biologicals s.a. rue de l'institut 89 b-1330 rixensart, belgium - mumps vaccine, rit, measles virus, schwarz strain, rubella virus, wistar ra - powder and solvent for solution for injection - measles virus - schwarz strain rubella virus - wistar ra27/3 strain mumps vaccine rit 4385 - vaccines